Apg Asset Management N.V. Alkermes Plc. Transaction History

Apg Asset Management N.V.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$26.4 - $32.56 $1.08 Million - $1.33 Million	40,800 Added 48.11%	125,600 $3.4 Million
Q4 2023 Feb 13, 2024	BUY	$23.37 - $28.68 $801,591 - $983,724	34,300 Added 67.92%	84,800 $2.35 Million
Q3 2023 Nov 14, 2023	BUY	$27.17 - $31.97 $1.37 Million - $1.61 Million	50,500 New	50,500 $1.41 Million
Q2 2022 Aug 12, 2022	SELL	$26.4 - $30.54 $1.2 Million - $1.39 Million	-45,537 Reduced 74.97%	15,200 $433,000
Q1 2020 May 14, 2020	BUY	$13.06 - $21.24 $239,220 - $389,053	18,317 Added 43.18%	60,737 $1.97 Million
Q4 2019 Feb 13, 2020	SELL	$17.29 - $21.74 $840,242 - $1.06 Million	-48,597 Reduced 53.39%	42,420 $771,000
Q3 2019 Nov 08, 2019	BUY	$19.51 - $24.28 $590,762 - $735,198	30,280 Added 49.85%	91,017 $1.63 Million
Q2 2018 Aug 13, 2018	SELL	$40.56 - $51.36 $158,184 - $200,304	-3,900 Reduced 6.03%	60,737 $2.14 Million
Q4 2017 Jan 24, 2018	SELL	$47.69 - $55.39 $782,163 - $908,451	-16,401 Reduced 20.24%	64,637 $2.95 Million
Q3 2017 Oct 19, 2017	BUY	$49.16 - $54.45 $3.98 Million - $4.41 Million	81,038	81,038 $4.12 Million

362

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.88B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Apg Asset Management N.V., based on Form 13F filings with the SEC.

Stay updated on Apg Asset Management N.V. with notifications on news.